THERAPEUTIC CLASS

Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

---

Among the 20,816 eligible PCI patients who were included in this study, there were 1578 and 779 patients in the clopidogrel and
ticagrelor groups, respectively, after PSM, their clinical parameters were well matched. Patients receiving ticagrelor showed comparable NACE risk compared with those treated by clopidogrel (5.3% vs. 5.1%, P = 0.842). Furthermore, ticagrelor might reduce the MACCE risk in patients with low bleeding risk but increase MACCE in patients with moderate‑to‑high bleeding potential (ticagrelor vs. clopidogrel, low bleeding risk: 2.5% vs. 4.9%, P = 0.022; moderate‑to‑high bleeding risk: 4.8% vs. 3.0%, P = 0.225; interaction P = 0.021), with vast differences in all bleeding (low bleeding risk: 1.5% vs. 0.8%, P = 0.210; moderate‑to‑high bleeding risk: 4.8% vs. 3.0%, P = 0.002; interaction P = 0.296).

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Cardiovascular & Hematopoietic System
Vaclo

Specific Detail Info

Chinese Medical Journal ¦ September 5, 2018 ¦ Volume 131 ¦ Issue 17

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment